Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Aug;70(2):171–179. doi: 10.1111/j.1365-2125.2010.03696.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Journal compilation © 2010 The British Pharmacological Society

PMC Copyright notice

FSSG scores over the trial period between the two treatment arms in subgroups of patients according to baseline scores. The upper two lines (red) indicate patients with baseline FSSG scores >18 points and the lower two lines (blue) refer to those with 18 points or fewer. Changes of symptom scores between the two medications were different only in the subgroup with baseline FSSG scores >18 at week 4. Data are expressed as mean ± SEM. FSSG, frequency scale for symptoms of gastro-oesophageal reflux disease. Placebo-mosapride () (); Mosapride-placebo () ()

Inline graphic — FSSG scores over the trial period between the two treatment arms in subgroups of patients according to baseline scores. The upper two lines (red) indicate patients with baseline FSSG scores >18 points and the lower two lines (blue) refer to those with 18 points or fewer. Changes of symptom scores between the two medications were different only in the subgroup with baseline FSSG scores >18 at week 4. Data are expressed as mean ± SEM. FSSG, frequency scale for symptoms of gastro-oesophageal reflux disease. Placebo-mosapride () (); Mosapride-placebo () ()